IMV Inc
IMV
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.12M
Close$
Share Statistics
| Market cap | $13.12 Million |
|---|---|
| Enterprise Value | $20.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.61 |
| Beta | 1.52 |
| Outstanding Shares | 8,343,455 |
Return
| Return on Equity | 554.67% |
|---|---|
| Return on Assets | -116.81% |
| Return on Invested Capital | -175.43% |
Valuation & Multiples
| P/E Ratio | -0.18 |
|---|---|
| PEG | 0.6 |
| Price to Sales | - |
| Price to Book Ratio | -0.82 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.54 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.39 |
| Debt to Equity | -4.38 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About IMV Inc
63 employees
CEO: Andrew Hall IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both soli...